| CAS NO: | 82034-46-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 466.95 |
|---|---|
| Formula | C24H31ClO7 |
| CAS No. | 82034-46-6 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 93 mg/mL (199.2 mM) |
| Water:<1 mg/mL | |
| Ethanol: 4 mg/mL (8.6 mM) | |
| Solubility (In vivo) | Chloromethyl (11β,17α)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate (11β,17α)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxoa |
| Synonyms | Loteprednol Etabonate; Lotemax; Alrex; HGP-1; Loterox; Locort; P 5604; HGP1; Lenoxin, CDDD 5604 |
| In Vitro | In vitro activity: Loteprednol possesses a metabolically labile function, the 17beta-ester, that is designed to be rapidly deactivated in the systemic circulation. Loteprednol etabonate exhibits a binding affinity which is 4.3 times that of dexamethasone, both compounds having a Hill factor close to 1 whereas PJ90 and PJ91 does not show any affinity to the receptor. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Loteprednol etabonate administrated directly into the joint effectively blocks the inflammatory response. Loteprednol etabonate prevents the adverse inflammatory effects of antigen action in a rabbit acute experimental model for arthritis. Loteprednol etabonate (LE) (oral) reaches the upper GI tract effectively, but not the colon, due to absorption and/or decomposition in rats. Loteprednol etabonate (LE) shows a rapid, dose-dependent elimination with a total blood clearance (CLtotal) of higher than 60 ml/min/kg in rats. Loteprednol etabonate absorbes systemically, after topical administration, can be rapidly transformed to the inactive metabolites, and eliminates from the body mainly through the bile and urine. |
| Animal model | |
| Formulation & Dosage | |
| References | J Steroid Biochem Mol Biol. 1991 Feb;38(2):149-54; Pharmazie. 1999 Jan;54(1):58-61. |
m.cnreagent.com